Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer

RATIONALE: Radiofrequency ablation uses high-frequency electric current to kill tumor cells. CT-guided radiofrequency ablation may be effective treatment for lung cancer.

PURPOSE: Phase II trial to study the effectiveness of radiofrequency ablation in treating patients who have refractory or advanced lung cancer.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Lung Cancer Adenoma Bronchial Neoplasms Carcinoma, Bronchogenic Carcinoma, Non-Small-Cell Lung Hemic and Lymphatic Diseases Lung Diseases Lung Neoplasms Lymphatic Diseases Malignant Mesothelioma Mesothelioma Mesothelioma, Malignant Metastatic Cancer Neoplasm Metastasis Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Complex and Mixed Neoplasms, Glandular and Epithelial Neoplasms, Mesothelial Neoplastic Processes Pathologic Processes Pathological Conditions, Signs and Symptoms Pleural Neoplasms Respiratory Tract Diseases Respiratory Tract Neoplasms Small Cell Lung Carcinoma Thoracic Neoplasms Thymoma Thymoma and Thymic Carcinoma Thymus Neoplasms

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Jonsson Comprehensive Cancer Center, UCLA

Los Angeles, California, 90095-1781, United States

About this study

OBJECTIVES:

Determine the safety and toxicity of radiofrequency ablation in patients with refractory or advanced pulmonary malignancies.
Determine the efficacy of this treatment, in terms of local control, in these patients.
Determine whether CT scan is a reasonable imaging assessment tool for treatment delivery and follow-up in these patients.

OUTLINE: Patients undergo percutaneous CT-guided radiofrequency ablation directly to the tumor over 2 hours.

Patients are followed at 1, 3, 6, and 12 months.

PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Diagnosis of a primary or secondary intrathoracic malignancy

Any cell type or origin
Involving the intrapulmonary, mediastinal, or pleural/chest wall
Inoperable primary or metastatic cancer to the lung
Refractory to or not amenable to conventional therapy (e.g., surgery, chemotherapy, or radiotherapy)
Single or multiple lesions that are non-contiguous with vital structures or organs such as:
Trachea
Heart
Aorta
Great vessels
Esophagus
Less than 5 cm in largest dimension
Accessible via percutaneous transthoracic route
Hepatic:

Coagulation profile normal

Treatment and study plan

Radiofrequency ablation

Procedure

Sponsors and collaborators

Lead sponsor

Jonsson Comprehensive Cancer Center

Other

Registry information

Official study title

Radiofrequency Ablation of Pulmonary Malignancy

Important dates

Study start: 2000
Primary completion: 2006
First posted: Jan 27, 2003
Registry last updated: Aug 3, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed